Treating Cardiovascular and

Inflammatory Diseases by

Reinforcing Natural

Mechanisms of Cell and

Organ Protection

Unlocking the Full Therapeutic Value of Natural Cell Protection Pathways

OMEICOS Therapeutics is focused on developing therapies that can have a significant impact on cardiovascular and inflammatory diseases, in ophthalmology and other therapeutic areas. Our pipeline is based on our proprietary approach to target one of nature’s most important cell-protective pathways and industry-leading knowledge of omega-3 fatty acid metabolism and biology.

OMEICOS lead compound, OMT-28, has most recently advanced into a double-blinded, placebo-controlled, multi-center Phase 2 clinical trial in patients suffering from Atrial Fibrillation – less than 6 years after founding the company in Berlin. The trial is aimed at establishing a robust clinical proof-of-concept and a ready to Phase 3 package for a fast transition into pivotal trials.

Beyond Atrial Fibrillation, the company is establishing a broader pipeline with initial work focusing on other cardiovascular conditions and ophthalmological indications, the latter driven by the US-based subsidiary OMEICOS Ophthalmics.

Latest Press Release

September 3, 2019
OMEICOS Therapeutics Appoints Dr Simon Russell as Chief Business Officer
Read more

Upcoming Events

January 11 – 14, 2021
Read more